GSK And Novartis Hit With $3m Fine In Australia For Misleading Voltaren Claims
Executive Summary
Marketing Voltaren Osteo Gel as more effective for treating osteoarthritis than the identically formulated Voltaren Emugel has landed GSK and Novartis with a substantial fine for breaching Australian Consumer Law.